<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426296</url>
  </required_header>
  <id_info>
    <org_study_id>COL102060</org_study_id>
    <nct_id>NCT00426296</nct_id>
  </id_info>
  <brief_title>SHARE: Simple HAART With Abacavir, Reyataz, and Epivir</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Na√Øve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Alliance for Research &amp; Education - Infectious Diseases, LLC.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Alliance for Research &amp; Education - Infectious Diseases, LLC.</source>
  <brief_summary>
    <textblock>
      SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24
      weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA
      &lt;50 copies/mL at entry
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Lipodystrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir (Reyataz)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir (Norvir)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir
             (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen

          -  Viral load &lt;50 copies/ml

        Exclusion Criteria:

          -  Viral load &gt;50 copies/ml

          -  Having taken more than one antiretroviral regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard A Elion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Whitman-Walker Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard A. Elion, MD</last_name>
    <email>drrelion@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Whitman-Walker Clinic</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Elion, MD</last_name>
      <email>drrelion@aol.com</email>
    </contact>
    <investigator>
      <last_name>Richard A Elion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>October 30, 2007</last_update_submitted>
  <last_update_submitted_qc>October 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Reyataz</keyword>
  <keyword>atazanavir</keyword>
  <keyword>Norvir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>Boosted</keyword>
  <keyword>Lipodystrophy</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

